Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...
Novo Nordisk's new obesity drug trial data disappoints again
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Data on new Novo Nordisk obesity drug disappoints in trial, stirs worries Lilly gaining edge in sector
Novo Nordisk on Monday revealed data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares ...
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...
Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Fierce Pharma18h
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
US FDA to hold off action on weight-loss drug copies pending court ruling
The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...